The financials
Harmony Biosciences Holdings, Inc. by the numbers
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $215M in Q1 2026 (quarter ended March 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $32M (15% of revenue). For the full year FY2025, revenue was $868M (+22% year on year) and net income $159M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $215M | $185M | +17% |
| Gross profit | $171M | $153M | +12% |
| Operating income | $37M | $56M | −34% |
| Net income | $32M | $46M | −29% |
| Diluted EPS | $0.55 | $0.78 | −29% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q1 2026Total $215.4M (-10%)
Rare Neurological Diseases grew +17% year on year
Segment Latestquarter on quarteryear on year
- Rare Neurological Diseases$215.4M$215.4MQoQ -10%year on year +17%-10%+17%